Ventavis and Keppra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ventavis (iloprost) and Keppra (levetiracetam). Common drug interactions include dyspnoea among females and convulsion among males.

The phase IV clinical study analyzes what interactions people have when they take Ventavis and Keppra. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Ventavis?

Ventavis has active ingredients of iloprost. eHealthMe is studying from 11,982 Ventavis users. Check the latest studies of Ventavis.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.



On Aug, 11, 2026

22 people who take Ventavis and Keppra together, and have interactions are studied.

Ventavis and Keppra drug interactions.

What are the common drug interactions of Ventavis and Keppra, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Cough
  3. Dementia (madness)
  4. Diarrhoea
  5. Dizziness
  6. Dysstasia (difficulty in standing)
  7. Ear infection
  8. Fatigue (feeling of tiredness)
  9. Fear
  10. Hallucination (an experience involving the perception of something not present)

male:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  3. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  4. Chest pain
  5. Cough
  6. Dyspnoea (difficult or laboured respiration)
  7. Embolism arterial (blood clot that has travelled through your arteries and become stuck)
  8. Fatigue (feeling of tiredness)
  9. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  10. Headache (pain in head)

What are the common drug interactions of Ventavis and Keppra, by age (0-1 to 60+)? *:

0-1:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  3. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  4. Obstructive airways disorder (a progressive disease that makes it hard to breathe)

2-9:

n/a

10-19:

  1. Death
  2. Dyspnoea (difficult or laboured respiration)

20-29:

n/a

30-39:

  1. Cough
  2. Dementia (madness)
  3. Diarrhoea
  4. Dizziness
  5. Dyspnoea (difficult or laboured respiration)
  6. Dysstasia (difficulty in standing)
  7. Ear infection
  8. Fatigue (feeling of tiredness)
  9. Fear
  10. Hallucination (an experience involving the perception of something not present)

40-49:

  1. Cerebral haemorrhage (bleeding within the brain)
  2. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  3. Chest pain
  4. Death
  5. Dizziness
  6. Embolism arterial (blood clot that has travelled through your arteries and become stuck)
  7. Fatigue (feeling of tiredness)
  8. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  9. Headache (pain in head)
  10. Loss of consciousness

50-59:

  1. Fluid retention (an abnormal accumulation of fluid in the blood)
  2. Weight increased
  3. Upper respiratory tract infection
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

60+:

  1. Arrhythmia (irregular heartbeat)
  2. Breast cancer
  3. Cardiac arrest
  4. Haemorrhage (bleeding)
  5. Hypotension (abnormally low blood pressure)
  6. Incoherent (talking in a confused and unclear way)
  7. Muscular weakness (muscle weakness)
  8. Non-small cell lung cancer metastatic (type of epithelial lung cancer spreads to other parts)
  9. Weight increased

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 14 people, 63.64%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 8 people, 36.36%
  3. Cough: 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Ventavis and Keppra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ventavis and Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ventavis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ventavis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Keppra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on iloprost and levetiracetam (the active ingredients of Ventavis and Keppra, respectively), and Ventavis and Keppra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: